These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30369094)

  • 1. Are the real-life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?
    Higham AK; Tahir MI; Gala K; Verroiopoulos G
    Acta Ophthalmol; 2019 Mar; 97(2):e322-e323. PubMed ID: 30369094
    [No Abstract]   [Full Text] [Related]  

  • 2. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
    Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
    Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 6. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
    Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
    Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical question.
    Moisseiev E; Loewenstein A
    Eye (Lond); 2019 Nov; 33(11):1677-1678. PubMed ID: 31471564
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
    Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
    Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.
    Lindboe JB; Brynskov T; Sørensen TL; Schmidt Laugesen C
    Acta Ophthalmol; 2024 Jun; 102(4):e661-e662. PubMed ID: 38525896
    [No Abstract]   [Full Text] [Related]  

  • 11. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.
    Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T
    Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
    Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
    Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
    Jampol LM; Glassman AR; Bressler NM
    JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
    [No Abstract]   [Full Text] [Related]  

  • 17. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper.
    Avitabile T; Azzolini C; Bandello F; Boscia F; De Falco S; Fornasari D; Lanzetta P; Mastropasqua L; Midena E; Ricci F; Staurenghi G; Varano M
    Eur J Ophthalmol; 2017 Nov; 27(6):627-639. PubMed ID: 29077188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Findings From Diabetic Retinopathy Clinical Research Retina Network Protocol V Confirm a Role for Focal Laser Photocoagulation or Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: New Is Not Always Best.
    Peto T; Chakravarthy U
    JAMA Ophthalmol; 2019 Jul; 137(7):838-839. PubMed ID: 31037285
    [No Abstract]   [Full Text] [Related]  

  • 20. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
    Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
    Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.